Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments * Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable). * Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.
• Subjects who are 45-64 years old (inclusive) at the time of screening.
• Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.
• Be able and willing to follow all instructions and attend study visits.
• Have text messaging capabilities on their phone.
• Self-reported complaints of near vision blur when fully corrected at distance.
• Study confirmed near add that is between +0.75 D to +2.00 D OD/OS (inclusive).
• Spherical distance prescription between +1.00 D to -4.00 D OD/OS (inclusive).
• Cylinder power less than or equal to -1.00 D OD/OS.
• Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20/20 Snellen equivalent) or better OD/OS.